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Lung cancer is a leading cause of cancer-related 
death worldwide. That’s why numerous studies are di-
rected on estimation of etiology of this disease, search 
for tumor markers, and development of new strategies 
for lung cancer treatment. It is well recognized now that 
the etiology of lung cancer is closely related to smoking 
habits and is often associated with chronic pulmonary 
inflammation and underlying immune dysfunction. 
However, little is known yet about involvement of in-
nate immunity molecules, in particular, defensins, in 
lung tumorigenesis.
Defensins — cationic antimicrobial peptides — are 
important components of mucosal immunity which 
two major functions are thought to be direct antimi-
crobial action and modulation of innate and adaptive 
immunity in response to pathogens. According to 
accumulated evidences, expression of some alpha- 
or beta-defensins may be altered or deregulated in 
different tumor types, and these antimicrobials could 
play a complex and poorly understood role in cancer 
pathogenesis either promoting or suppressing tumor 
cell growth [1, 2].
In normalcy, defensins participate in antimicrobial 
protection of respiratory tract along with other defense 
molecules [3]. Mailfunction or altered expression of 
these peptide antibiotics has been well documented 
in a number of chronic lung pathologies, in particular, 
cystic fibrosis, reactive airway disease, tuberculosis and 
many other lung infections [4]. There are some data evi-
dencing on reduced levels of beta-defensin-2 (hBD-2) 
in sputum and pharyngeal washes of smokers versus 
nonsmokers with acute pneumonia [5] what points on 
possible smoking-dependent down-regulation of this 
peptide in airway epithelium. At the same time, up-to-
date there are scarce data for defensin expression pat-
terns in lung cancer. In our recent pilot study [6] we have 
recorded an altered expression of hBD-1-4 mRNAs in 
lung cancer samples versus normal lung tissue.
In this regard we aimed to analyze further the 
expression patterns of hBD-2 in human lung tumor 
samples using immunohistochemical approach.
MATERIALS AND METHODS
In the study, 31 samples of surgically resected 
human lung tumors of different histological type were 
studied. The tissue samples were obtained during the 
surgical treatment of lung cancer patients cured in 
the Thoracic Department of National Cancer Institute 
(Kyiv, Ukraine) in 2001–2008 (Head of the Dept., prof. 
V.L.Ganul). Immediately after surgical removal, tissue 
samples were placed in liquid nitrogen and stored at 
-70 oC until use. The patients did not receive chemo- or 
radiotherapy prior to the surgery. All patients provided 
an informed written consent to perform the study, and 
the present research was approved by Ethic Board of 
the Institute. Histological type and differentiation grade 
of lung tumors has been estimated by clinical patholo-
gists (National Cancer Institute, Dept. Pathol. Anat. Dr. 
E.N. Kovalchuk and Dr. I.N. Troitskaya). From 31 lung 
tumor samples, 1 tumor was diagnosed as small-cell 
lung cancer (SCLC), and 30 — as non-small cell lung 
cancer (NSCLC). The last group of tumors included 
1 case of clear cell large cell lung cancer, 9 cases of 
squamous cell carcinoma (SCC), and 20 cases of ad-
enocarcinoma (AC). The clinico-pathological charac-
teristics of lung cancer cases are presented in Table 1.
Immunohistochemical analysis. Tumor tissue 
samples were fixed in 4% formaldehyde for 24 h at 
room temperature, then dehydrated in 50%, 70%, 80%, 
90%, 96% spirits, treated with chloroform, saturated 
with paraffin at 56 оС for 30 min and placed in paraffin 
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blocks. 5 µm tissue slides were prepared with the use 
of microtom REICHERT-JUNG Mod. 1140/Autocut.
Immunohistochemical analysis of protein expres-
sion has been performed on paraffin slides with the 
use of a number of primary antibodies listed below, 
EnVision System and DAB reagent (DAKO, Denmark). 
The slides were twice deparaffinized with xylol (by 
20 min), twice washed with 96% ethanol by 10 min, and 
washed with distilled water. The slides were placed in 
citrate buffer for 30 min and incubated in water bath 
at 95 ˚ С. To block endogenous peroxidase activity, the 
slides were treated with Peroxidase-Blocking Reagent 
(DAKO, Denmark) according to instructions of the 
manufacturer.
Incubation with primary antibodies (rat polyclonal 
anti-hBD-2-Abs (Santa-Cruz, USA) 1 : 100; mouse 
monoclonal anti-PCNA-Abs (Dako, Denmark) — 1 : 
200; mouse monoclonal anti-Bcl-2 (Dako, Den-
mark) — 1 : 200) was carried out for 1 h at room tem-
perature in humidified atmosphere. To detect binding 
of primary antibodies, the slides were incubated 
with visualization system EnVision System (DAKO, 
Denmark) for 1 h at room temperature in humidified 
atmosphere. Then peroxidase activity was developed 
using diaminobenzidine solution (DAB, DakoCytoma-
tion, Denmark). Cell nuclei were stained with Meyer’s 
hematoxylin. As negative control, the slides treated 
with normal mouse serum followed by DAB, were used. 
Microscopic examination was done with the use of Carl 
Zeiss Jena microscope (Germany).
The level of protein expression was evaluated by 
the percent of positive cells or/and by intensity of 
immunostaining with the use of H-score (counted as 
follows: H-score = 1 x W + 2 x M + 3 x S, where W, M, 
S are the percents of cells with weak, moderate and 
strong staining intensity respectively).
Statistical analysis. The statistical significance of 
the differences between the values (percent of hBD-
2-positive cells, expressed as M±m) was assessed by 
the Student’s t-test. Values p < 0.05 were considered 
statistically significant.
RESULTS
In our research we have studied expression of 
hBD-2 in 31 lung tumor tissue samples from the 
same patients. In order to find possible association 
of hBD-2 expression with the processes of lung cell 
proliferation or apoptosis, expression of proliferation 
cell nuclear antigen (PCNA) and antiapoptotic Bcl-
2 protein has been studied as well.
Lung tumor samples were represented by histologi-
cally heterogenous group composed from 1 sample of 
SCLC and 30 samples of NSCLC; the latest group was 
composed from 1 case of clear cell large cell, 9 cases 
of SCC (8 low differentiatied (LD) tumors, 1 moder-
ately differentiated (MD) tumors), and 20 cases of AC 
(6 LD AC, 6 MD AC, 2 of MD/LD AC, 1 case of mixed 
AC + SCC type, 1 case of papillary cancer, 2 cases of 
bronchoalveolar highly differentiatied (HD) cancer, and 
2 cases of AC with the regions of clear cell carcinoma) 
(Table 1).
Table 1. The data for lung cancer patients and lung tumor samples used 
in the study
N Case Gen-der Age
TNM clas-
sification Histological type
Differ-
entiation 
grade
Addition-
al infor-
mation
1 A M 52 T2N0M0 Small cell lung 
cancer
PL
2 B M - T2N0M0 Clear cell large 
cell lung cancer
PL
3 C1 M 62 T2N0M0 SCC LD CL
4 C2 M 72 T2N2M1 SCC LD PL
5 C3 M 68 T1N0M0 SCC LD PL
6 C4 M 58 T2N2M0 SCC LD PL
7 C5 M 68 T2N0M0 SCC LD PL
8 C6 M 78 T2N0M0 SCC LD PL
9 C7 M 57 T2N1M0 SCC LD PL
10 C8 M 57 T2N0M0 SCC LD CL
11 C10 M 50 T2N1M0 SCC MD PL
12 D1 F 67 T2N0M0 AC LD PL
13 D2 M 72 T3N2M0 AC MD PL
14 D3 M 57 T2N0M0 Papillary AC with 
mucus production
LD PL
15 D4 M 59 T2N0M0 AC MD PL
16 D6 M 54 T2N1M0 AC MD PL
17 D7 F 54 T1N0M0 AC LD PL
18 D8 M 55 T2N0M0 AC LD PL
19 D9 M 56 T2N2M0 AC LD PL
20 D10 M 41 T1N0M0 AC LD PL
21 D11 M 76 T2N1M0 AC with regions 
of solid clear cell 
cancer
LD PL
22 D12 F 63 T2N1M0 AC MD/LD PL
23 D13 M 44 T2N1M0 AC MD/LD PL
24 D14 M 40 T2N1M0 AC MD PL
25 D15 M 65 T2N1M0 Mixed type (AC + 
SCC)
PL
26 D16 M 54 T2N2M0 AC MD PL
27 D17 F 64 T2N2M0 AC MD PL
28 D18 M 69 T3N0M0 AC LD PL
29 D19 F 63 T1N0M0 Bronchoalveolar 
cancer
HD PL
30 D20 F 60 T1N0M0 Bronchoalveolar 
cancer
HD PL
31 D21 M 63 T2N2M0 AC with regions 
of solid clear cell 
cancer
LD PL
Notes: tumor differentiation: LD — low-differentiated; MD — moderately-dif-
ferentiated; HD — highly-differentiated; SCC — squamous cell carcinoma; 
AC — adenocarcinoma; PL — peripheral localization, CL — central localization.
The study has been performed on paraffin em-
bedded tissue blocks of the lung tumors with the use 
of immunohistochemical approach (Table 2, Fig. 1). 
Immunohistochemical analysis has revealed that 
the studied SCC cases of peripheral localization are 
characterized by moderate to very-high expression of 
hBD-2 (6 from 7 cases), while 2 cases of SCCs local-
ized in bronchus express low levels of hBD-2 protein (< 
10%). High percent of cells expressing PCNA or/and 
Bcl-2 proteins was detected just in 1/3 of SCC cases.
Immunohistochemical analysis of hBD-2 expres-
sion in AC samples has shown that AC of LD grade 
differs from AC of MD grade by lower hBD-2 expres-
sion (p < 0.05) (Table 2, Fig. 1). PCNA and Bcl-2 ex-
pression levels differ between the AC samples in a 
wide range (however, both markers were negative in 
HD bronchoalveolar cancer). There was observed no 
significant correlation between expression levels of 
mentioned above markers.
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Table 2. Immunohistochemical analysis of hBD-2, PCNA, Bcl-2 expres-
sion in human lung tumor samples
№ Case
Expression level
hBD-2 PCNA Bcl-2
% positive cells H-scoring % positive cells % positive cells
Small cell lung cancer
1 A < 5% 5 90% 80%
Non-small cell lung cancer:
Clear cell large cell lung cancer
2 B 15% 15 95% 50%
Squamous cell carcinoma (LD)
3 C1 10% 10 15% 30%
4 C2 20% 25 20% 7%
5 C3 58% 130 32% 25%
6 C4 45% 85 55% 60%
7 C5 100% 241 64% 60%
8 C6 50% 118 - 6%
9 C7 100% 200 0.5% 5%
10 C8 10% 15 20% 10%
Squamous cell carcinoma (MD)
11 C10 40% 65 50% 10%
Adenocarcinoma (LD)
12 D1 < 5% 10 50% 25%
13 D7 30% 56 80% 40%
14 D8 20% 29 40% 40%
15 D9 < 5% 3 35% 35%
16 D10 15% 30 20% 40%
17 D18 40% 172 35% 20%
Adenocarcinoma (MD)
18 D2 23% 137 60% 60%
19 D4 < 5% 3 ND ND
20 D6 50% 100 60% 60%
21 D14 98% 219 - 25%
22 D16 90% 196 - 70%
23 D17 98% 138 - 10%
Adenocarcinoma (MD/LD)
24 D12 50% 110 10% < 5%
25 D13 50% 142 50% 50%
AC with regions of solid clear cell cancer
26 D11 35% 64 30% 0.5%
27 D21 100% 150 40% 40%
Bronchoalveolar cancer (HD)
28 D19 45% 78 - 3%
29 D20 81% 216 1% -
Mixed type (AC + SCC)
30 D15 100% 111 25% 10%
Papillary AC
31 D3 10% 81 30% 15%
According to the data of IHC analysis, beta-defen-
sin-2 is distributed in tumor cell cytoplasm as well as 
in perinuclear space (Fig. 2).
DISCUSSION
Involvement of human antimicrobial peptides, in 
particular, defensins in antimicrobial protection of 
airways has been in spite of interest of many scientific 
groups. The patterns of hBD-2 expression in surface 
epithelial cells of human lung and bronchus has been 
firstly described in 1998 in the detailed research of 
Bals et al [7] who have showed hBD-2 up-regulation in 
conditions of chronic inflammation. In a short time the 
molecular mechanisms of hBD-2 induction in respira-
tory hTBE cells via NF-kB activation with involvement of 
CD14 and TLR has been reported in the study of Beker 
et al [8]. Since then, mailfunction or altered levels of 
defensins have been reported in several pulmonary 
disorders, in particular, pulmonary fibrosis, panbron-
chiolitis, alveolar proteinosis, acute respiratory distress 
syndrome, lung transplantation, etc [9]; at present time 
the exact role of defensins, multifunctional molecules 
with direct antimicrobial activity and immunomodula-
tory properties, in lung disorders is not fully understood 
and remains largely unstudied in lung cancer.
To our knowledge, our study is among the first ones 
where beta-defensin-2 expression has been recorded 
in human lung tumor samples with the use of immu-
nohistochemical analysis. It has been revealed that all 
lung tumor samples independently on their histological 
type express hBD-2 peptide, however at different lev-
els (from < 5% to 100% cells). In the majority of cases 
hBD-2 expression is moderate, in 4 cases very low (< 
5% cells), and nearly in 1/3 of cases it is very high (close 
to 100% of cells, or > 200 by H-score). These data are 
a b
c d
Fig.1. Immunohistochemical analysis of hBD-2 expression in lung squamous cell carcinoma (cases C4 (a), C5 (b)) and lung ad-
enocarcinoma (cases D18 (c), D21(d))
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in some agreement with observations of Arimura et al. 
[10] who have recorded significantly elevated concen-
trations of hBD-1 and high concentrations of hBD-2 in 
blood serum of lung cancer patients compared to pa-
tients with pneumonia and healthy donors, and the data 
of our earlier pilot study that has documented the fact 
that an up-regulation of hBD-1 and hBD-2 mRNAs is a 
frequent event in both lung SCC and AC compared to 
normal lung tissue samples [6]. Unfortunately, as far as 
the data on the history of the patients studied in present 
study (concominant lung pathologies, smoking habits) 
were unavailable, there are no grounds to speculate on 
possible causes of elevated expression of the defensin 
in lung tumor tissues.
The hBD-2 expression levels in these samples 
seem to be not correlated with expression of prolif-
eration marker PCNA and antiapoptotic Bcl-2 pro-
tein. Interestingly, we have detected also that in lung 
adenocarcinoma hBD-2 expression depend on tumor 
differentiation grade — low differentiated tumors differ 
from moderately differentiated ones by significantly 
lower percent of hBD-2 expressing cells (p < 0.05).
Functional significance of human defensin-2 up-
regulation in lung tumor cells and possible relation 
between its expression and tumor differentiation grade 
remain to be studied in further researches.
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Fig. 2. Immunohistochemical analysis of hBD-2 expression in 
lung squamous cell carcinoma (case C7 (a)) and lung adeno-
carcinoma (cases D14 (b), D16 (c))
Experimental Oncology 32, 277–279, 2010 (December) 277
Isolated splenic metastasis is rare in colorectal 
cancer. Malign melanoma, breast and ovarian cancers 
are the most common solid tumors in which splenic 
metastasis occurs [1]. Isolated splenic metastasis may 
be synchronous or metachronous. The rates of iso-
lated splenic metastasis are reported as 4.4% for colon 
cancer and 1.6% for rectum cancer. It is ge nerally 
diagnosed while evaluating asymptomatic cancer 
patients with increasing levels of carcinoembryonic 
antigen (CEA). In this report, our aim is to report two 
cases with atypical metastasis.
Case 1. A 58-year old male patient was admitted to 
the hospital with ileus a year ago. Hemicolectomy was 
performed after the diagnosis of colon carcinoma. His-
topathology revealed colon adenocarcinoma without 
lymph node involvement (stage III). He was given adju-
vant 5-flurouracil (5-FU)-based chemotherapy. He had 
a CEA level elevation [4.62 ng/mL (N: 0–3.4)] in blood 
serum fifteen months after hemicolectomy without any 
evidence of local or distant metastasis on evaluation. 
However, a splenic mass was diagnosed 5 months 
later. Splenectomy was performed, and histopathology 
revealed the metastasis of colon adenocarcinoma in 
the spleen. A 3.5 x 3 x 2.5 cm size tumor was located 
just beneath the capsule of the spleen (Fig. 1, a, b). 
Chemotherapy which consisted of 5-FU, leucovorine 
(LV) and oxaliplatin (FOLFOX-4) was given. He had a 
second relapse in the splenic localization (5.5 x 3 cm) 
after 11 months of first relapse. An increased uptake of 
18-fluorodeoxyglucose (18-FDG) was observed only 
in this lesion with standardized uptake value (SUVmax) 
of 11.7 on 18-FDG-positron emission computerized 
tomography (18-FDG-PET-CT) (Fig. 2). Palliative che-
motherapy including 5-FU, LV, irinotecan (FOLFIRI) and 
bevacizumab was started. The patient has no evidence 
of progression for 7 months after the second relapse.
Case 2. A 51-year old male patient was admitted 
with 2 months of constipation and hematochezia. He 
was diagnosed as having rectal adenocarcinoma with 
bilateral lung metastasis and a solitary nodular lesion 
(1.8 x 1.5  cm) in the upper pole of right kidney. Renal 
mass SUVmax was 13.1 on 18-FDG-PET-CT (Fig. 3). 
Renal aspiration biopsy was performed to determine 
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Fig. 1. Focal necrosis and atypical prismatic tumor cells with 
abortive organization, hematoxylin and eosin staining — 10X 
(a), 40X (b)
